Forbes November 13, 2024
Alex Knapp

Insilico Medicine announced results from a clinical trial of ISM001-055, which the company designed using generative AI in order to treat idiopathic pulmonary fibrosis, a chronic lung disease affecting around 100,000 Americans that makes breathing increasingly difficult as it progresses.

The phase IIa study, conducted in China, involved 71 patients who were randomized to either receive a placebo, a daily 30mg pill, a twice-daily dose of a 30mg pill, or a daily 60 mg pill. Across all patients, the majority of side effects were mild or moderate, the company said. Those who received the highest dose law improvement in lung function compared to the placebo group. The 60mg group also saw improvements in their quality of life.

The Cambridge-based company...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Technology, Trends
2024: record year for AI trials
Future Trends for Clinical Trials in 2025 and Beyond
The Future of Clinical Trials: Four Key Trends to Watch in 2025
Small cell lung cancer: Navigating the global clinical trial landscape
Generative AI has ‘potential to revolutionise clinical development’

Share This Article